<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02120924</url>
  </required_header>
  <id_info>
    <org_study_id>13-1014</org_study_id>
    <nct_id>NCT02120924</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference Listed Finacea® (Azelaic Acid) Gel, 15% in Patients With Moderate Facial Rosacea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic
      Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of
      moderate facial rosacea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FINACEA® (azelaic acid) GEL, 15% contains azelaic acid, a naturally occurring saturated
      dicarboxylic acid that has proven anti-inflammatory effects, as well as anti-keratinizing and
      antimicrobial action, although its mechanism of action in rosacea is not well understood.
      This study will be conducted in compliance with the protocol, Good Clinical Practices (GCP)
      and the applicable regulatory requirement(s). Marketed by Intendis, Finacea® (azelaic acid)
      Gel, 15% is a safe and effective topical therapy used for the treatment of moderate facial
      rosacea. Watson Laboratories, Inc. has developed a generic formulation of azelaic acid 15%
      gel and the current study is designed to evaluate the safety and efficacy of this
      formulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts in PP population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With a Clinical Response of &quot;Success&quot; at Week 12 Using Investigator Global Evaluation (IGE)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The secondary endpoint is the clinical response of &quot;success&quot; or &quot;failure&quot; at Week 12 on the IGE. Success is defined as an IGE score of 0 (clear) or 1 (almost clear). Any subject who is not considered to be a success will be considered to be a failure.
Score-Grade-Definition 0 - Clear - No inflammatory lesions present; at most, mild erythema.
- Almost Clear - Very mild erythema present. Very few small papules/pustules.
- Mild - Mild erythema. Several small papules/pustules.
- Moderate - Moderate erythema. Several small or large papules/pustules, and up to two nodules.
- Severe - Severe erythema. Numerous small and/or large papules/pustules, up to several nodules.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1009</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Finacea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Finacea® (azelaic acid) Gel, 15% (Intendis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azelaic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gel Vehicle of the test product (Watson Laboratories, Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid</intervention_name>
    <description>Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
    <arm_group_label>Azelaic Acid</arm_group_label>
    <other_name>Generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finacea</intervention_name>
    <description>Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
    <arm_group_label>Finacea</arm_group_label>
    <other_name>Finacea® (azelaic acid) Gel, 15% (Intendis)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant female ≥18 years-of-age with a clinical diagnosis of
             moderate facial rosacea.

          -  Patient must have at least eight and not more than fifty inflammatory facial lesions
             (i.e., papules/pustules) and ≤2 nodules on the face. For the purposes of study
             treatment and evaluation, these lesions should be limited to the facial treatment area
             including those present on the nose. Lesions involving the eyes, and scalp should be
             excluded from the count.

          -  Patients must have persistent erythema on the face with moderate (Definite redness,
             easily recognized) to Severe (Marked erythema; fiery red).

          -  Patients must have a mild to moderate score for telangiectasia on the face - Patients
             must have a definite clinical diagnosis of moderate facial rosacea as per the IGE

          -  Patient must be willing to minimize external factors that might trigger rosacea
             flare-ups (e.g., spicy foods, thermally hot foods and drinks, hot environments,
             prolonged sun exposure, strong winds and alcoholic beverages).

          -  Patient must be in general good health and free from any clinically significant
             disease other than rosacea, that might interfere with the study evaluations.

          -  Patient must be willing and able to understand and comply with the requirements of the
             study, apply the medication as instructed, return for the required treatment period
             visits, comply with therapy prohibitions, and be able to complete the study.

          -  Female Subjects of childbearing potential (excluding women who are
             surgicallysterilized or postmenopausal for at least 1 year), in addition to having a
             negative urine pregnancy test, must be willing to use an acceptable form of birth
             control during the study from the day of the first dose administration to 30 days
             after the last administration of study drug For the purpose of this study the
             following are considered acceptable methods of birth control: oral contraceptives,
             contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier
             methods (e.g., condom and spermicide), contraceptive injection (Depo-provera®),
             intrauterine device (IUD), hormonal IUD (Mirena®) and abstinence with a documented
             second acceptable method of birth control, should the patient become sexually active.
             Patients on hormonal contraception must be stabilized on the same type for at least
             three months prior to enrollment in the study and must not change the hormonal
             contraception during the study. Patients who had used hormonal contraception and
             stopped must have stopped no less than three months prior to the study. A sterile
             sexual partner is NOT considered an adequate form of birth control.

          -  All male patients must agree to use accepted methods of birth control with their
             partners, from the day of the first dose administration to 30 days after the last
             administration of study drug. Abstinence is an acceptable method of birth control.
             Female partners should use an acceptable method of birth control as described in the
             above Item Number 10.

          -  Patients who use make-up must have used the same brands/types of make-up for a minimum
             period of 14 days prior to study entry and must agree to use the same make-up,
             brand/type, or frequency of use, throughout the study.

        Exclusion Criteria:

          -  Pregnant or lactating or planning to become pregnant during the study period.

          -  Presence of any skin condition on the face that would interfere with the diagnosis or
             assessment of rosacea.

          -  Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere
             with diagnosis or assessment of rosacea.

          -  History of hypersensitivity or allergy to azelaic acid, propylene glycol or any other
             component of the formulation.

          -  The use within 6 months prior to baseline of oral retinoids (e.g. Accutane®) or
             therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are
             allowed).

          -  The use of estrogens or oral contraceptives for less than 3 months prior to baseline.

          -  The use within 1 month prior to baseline of:

               1. topical retinoids to the face;

               2. systemic antibiotics known to have an impact on the severity of facial rosacea
                  (e.g., containing tetracycline and its derivatives, erythromycin and its
                  derivatives, sulfamethoxazole, or trimethoprim);

               3. systemic corticosteroids (Note: intranasal and inhalational corticosteroids do
                  not require a washout and maybe used throughout the trial if the subject is on a
                  stable dose).

          -  Use within 2 weeks prior to baseline of:

               1. topical corticosteroids;

               2. topical antibiotics;

               3. topical medications for rosacea (e.g., metronidazole).

          -  Patients with moderate or severe rhinophyma, dense telangiectases (score 3, severe),
             or plaque-like facial edema.

          -  Patients with a severe irritation grade for erythema, dryness, scaling, pruritus,
             stinging/burning, and edema.

          -  Ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient
             severity to require topical or systemic antibiotics.

          -  A patient who has used a sauna during the 2 weeks prior to study entry and during the
             study.

          -  Patients who have performed wax epilation of the face within 14 days prior to baseline

          -  A patient who has a history of being unresponsive to topical azelaic acid therapy.

          -  A patient with bacterial folliculitis.

          -  A patient who consumes excessive alcohol, abuses licit or illicit drugs, or has a
             condition that could compromise the patient's ability to comply with study
             requirements.

          -  Patients who engage in activities that involve excessive or prolonged exposure to
             sunlight or weather extremes, such as wind or cold.

          -  A patient who has any clinically significant condition or situation, other than the
             condition being studied that, in the opinion of the Investigator, would interfere with
             the study evaluations or optimal participation in the study.

          -  A patient who has used any topical azelaic acid therapy within 30 days of baseline
             visit.

          -  Patients who have participated in an investigational drug study (i.e., patients have
             been treated with an Investigational Drug) within 30 days prior to baseline will be
             excluded from study participation. Patients who are participating in non-treatment
             studies such as observational studies or registry studies can be considered for
             inclusion.

          -  Patients who have been previously enrolled in this study.

          -  Patients who have had laser therapy (for telangiectasia or other conditions),
             electrodessication and phototherapy (e.g., ClearLight®) to the facial area within 180
             days prior to study entry.

          -  Patients who have had cosmetic procedures (e.g., facials) which may affect the
             efficacy and safety profile of the Investigational Product within 14 days prior to
             study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Capicchioni</last_name>
    <role>Study Director</role>
    <affiliation>Akesis, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 29</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Glenn Dale</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 7</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>University Place</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <results_first_submitted>April 9, 2020</results_first_submitted>
  <results_first_submitted_qc>May 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2020</results_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate facial rosacea</keyword>
  <keyword>Azelaic acid</keyword>
  <keyword>Rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azelaic Acid, 15% Topical Gel</title>
          <description>Test product: Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
        <group group_id="P2">
          <title>Finacea® (Azelaic Acid) Gel, 15% (Intendis)</title>
          <description>Reference product: Finacea® (azelaic acid) Gel, 15% (Intendis)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
        <group group_id="P3">
          <title>Gel Vehicle</title>
          <description>Placebo product: Gel Vehicle of the test product (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="404"/>
                <participants group_id="P2" count="403"/>
                <participants group_id="P3" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="357"/>
                <participants group_id="P3" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Compliance with IP</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Summary of Demographic characteristics in PP Population</population>
      <group_list>
        <group group_id="B1">
          <title>Azelaic Acid, 15% Topical Gel</title>
          <description>Test product: Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
        <group group_id="B2">
          <title>Finacea® (Azelaic Acid) Gel, 15%</title>
          <description>Reference product: Finacea® (azelaic acid) Gel, 15% (Intendis)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
        <group group_id="B3">
          <title>Gel Vehicle</title>
          <description>Placebo product: Gel Vehicle of the test product (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="293"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="127"/>
            <count group_id="B4" value="694"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" spread="12.71"/>
                    <measurement group_id="B2" value="50.0" spread="12.42"/>
                    <measurement group_id="B3" value="51.4" spread="11.73"/>
                    <measurement group_id="B4" value="50.8" spread="12.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="303"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="391"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="667"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts.</title>
        <description>Percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts in PP population.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid, 15% Topical Gel</title>
            <description>Test product: Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
          </group>
          <group group_id="O2">
            <title>Finacea® (Azelaic Acid) Gel, 15%</title>
            <description>Reference product: Finacea® (azelaic acid) Gel, 15% (Intendis)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
          </group>
          <group group_id="O3">
            <title>Gel Vehicle</title>
            <description>Placebo product (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts.</title>
          <description>Percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts in PP population.</description>
          <population>Per protocol population</population>
          <units>Percent change in lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.96" spread="29.394"/>
                    <measurement group_id="O2" value="-68.62" spread="27.415"/>
                    <measurement group_id="O3" value="-38.64" spread="46.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary endpoint was the percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts in PP population.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% CI for the ratio of Test/Reference means was contained within the interval [0.80, 1.25].</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Bioequivalence was established if the 90% CI for the ratio of Test/Reference means was contained within the interval [0.80, 1.25].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With a Clinical Response of &quot;Success&quot; at Week 12 Using Investigator Global Evaluation (IGE)</title>
        <description>The secondary endpoint is the clinical response of &quot;success&quot; or &quot;failure&quot; at Week 12 on the IGE. Success is defined as an IGE score of 0 (clear) or 1 (almost clear). Any subject who is not considered to be a success will be considered to be a failure.
Score-Grade-Definition 0 - Clear - No inflammatory lesions present; at most, mild erythema.
- Almost Clear - Very mild erythema present. Very few small papules/pustules.
- Mild - Mild erythema. Several small papules/pustules.
- Moderate - Moderate erythema. Several small or large papules/pustules, and up to two nodules.
- Severe - Severe erythema. Numerous small and/or large papules/pustules, up to several nodules.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>Analysis of Treatment Success Based on IGE Score at Week 12 in PP Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid, 15% Topical Gel</title>
            <description>Test product: Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
          </group>
          <group group_id="O2">
            <title>Finacea® (Azelaic Acid) Gel, 15%</title>
            <description>Reference product: Finacea® (azelaic acid) Gel, 15% (Intendis)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
          </group>
          <group group_id="O3">
            <title>Gel Vehicle</title>
            <description>Placebo product: Gel Vehicle of the test product (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With a Clinical Response of &quot;Success&quot; at Week 12 Using Investigator Global Evaluation (IGE)</title>
          <description>The secondary endpoint is the clinical response of &quot;success&quot; or &quot;failure&quot; at Week 12 on the IGE. Success is defined as an IGE score of 0 (clear) or 1 (almost clear). Any subject who is not considered to be a success will be considered to be a failure.
Score-Grade-Definition 0 - Clear - No inflammatory lesions present; at most, mild erythema.
- Almost Clear - Very mild erythema present. Very few small papules/pustules.
- Mild - Mild erythema. Several small papules/pustules.
- Moderate - Moderate erythema. Several small or large papules/pustules, and up to two nodules.
- Severe - Severe erythema. Numerous small and/or large papules/pustules, up to several nodules.</description>
          <population>Analysis of Treatment Success Based on IGE Score at Week 12 in PP Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided, continuity-corrected, 90% CI on the Test-to-Reference difference for the proportion of subjects with treatment success on the IGE was constructed.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.044</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>0.116</ci_upper_limit>
            <estimate_desc>Bioequivalence was established if the 90% CI for the difference was contained within the interval [-0.20, +0.20].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored and collected over a period of at least 12 weeks, through to study completion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Azelaic Acid, 15% Topical Gel</title>
          <description>Test product: Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
        <group group_id="E2">
          <title>Finacea® (Azelaic Acid) Gel, 15%</title>
          <description>Reference product: Finacea® (azelaic acid) Gel, 15% (Intendis)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
        <group group_id="E3">
          <title>Gel Vehicle</title>
          <description>Placebo product: Gel Vehicle of the test product (Watson Laboratories, Inc.)
Azelaic acid: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Tooth crowding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Alveolar osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Atypical pnuemonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Tonsillitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Invertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Muscoloskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dizziness exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Premenstrual headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals USA, Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedinfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

